# US 2016/0355805 A1 · Double Stranded Oligonucleotide Compounds Comprising Positional Modifications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355805 A1
- Document ID: US20160355805A1
- Status: Published application
- Kind: A1
- Application number: 14/996,493
- Filed: 2016-01-15
- Published: 2016-12-08
- Earliest claimed: 2013-08-23
- Assignees: Quark Pharmaceuticals, Inc.
- Applicants: Quark Pharmaceuticals, Inc.
- Inventors: Sharon Avkin-Nachum; Elena Feinstein; Leonid Beigelman
- Web page: https://patentgrep.com/patent/US20160355805A1

## CPC

- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/319: linked by 2'-5' linkages, i.e. having a free 3'-position
- C12N 2310/323: modified ring structure
- C12N 2310/344: Position-specific modifications, e.g. on every purine, at the 3'-end
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2320/50: Methods for regulating/modulating their activity
- C12N 2320/51: modulating the chemical stability, e.g. nuclease-resistance
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are double stranded RNA molecules which have been modified to exhibit one of the following, increased activity, enhanced nuclease stability, reduced off target activity and or reduced immunogenicity, to pharmaceutical compositions comprising such compounds and to methods of use. Further disclosed is a method for the synthesis of threose nucleic acid phosphoramidites and methods of use thereof.

## Claims

### Claim 1

A double stranded nucleic acid molecule having structure A1 set forth below:
(A1) 5′ (N)x-Z 3′ (antisense strand)
3′ Z′-(N′)y-z″ 5′ (sense strand)
wherein said double stranded nucleic acid molecule is an siRNA, siNA, or miRNA, and wherein each of N and N′ is a ribonucleotide that may be unmodified or modified, or an unconventional moiety;
wherein each of (N)x and (N′)y is an oligonucleotide in which each consecutive N or N′ is joined to the next N or N′ by a covalent bond;
wherein each of Z and Z′ is independently present or absent, but if present independently includes 1-5 consecutive nucleotides or non-nucleotide moieties or a combination thereof covalently attached at the 3′ terminus of the strand in which it is present;
wherein z″ may be present or absent, but if present is a capping moiety covalently attached at the 5′ terminus of (N′)y;
wherein each of x and y is independently an integer between 18 and 25;
wherein the sequence of (N′)y has complementarity to the sequence of (N)x, and (N)x comprises an antisense sequence complementary to a consecutive sequence in a target RNA; and
wherein the molecule comprises the following modification b and at least one of the following modifications a and c:
a. a 2′5′ nucleotide or a mirror nucleotide is present in (N)x in at least one of positions 5, 6, 7, 8, or 9 from the 5′ terminus;
b. a threose nucleic acid moiety is present in the sense strand at positions 14 and 16-19, positions 13-14 and 16-19, or positions 12-14 and 16-19, and a 2′5′ nucleotide is present in the same sense strand; and
c. from 1 to 10 2′5′ nucleotides are present in (N′)y at the 3′ terminal or penultimate positions,
wherein the threose nucleic acid is an L-alpha-threofuranosyl nucleotide.

### Claim 2 (depends on 1)

The double stranded nucleic acid molecule of claim 1, wherein x=y and each of x and y is 19, 20, 21, 22 or 23.

### Claim 3 (depends on 2)

The double stranded nucleic acid molecule of claim 2, wherein x=y=19.

### Claim 4 (depends on 1)

The double stranded nucleic acid molecule of claim 1, wherein the covalent bond joining each consecutive N or N′ is a phosphodiester bond.

### Claim 5 (depends on 1)

The double stranded nucleic acid molecule of claim 1, wherein the sequence of (N′)y is fully complementary to the sequence of (N)x.

### Claim 6 (depends on 1)

The double stranded nucleic acid molecule of claim 1, wherein the double stranded nucleic acid molecule comprises a mismatch to the target mRNA at the 5′ terminal ribonucleotide of the antisense strand.

### Claim at position 7

-9. (canceled)

### Claim 10 (depends on 1)

The double stranded nucleic acid molecule of claim 1, wherein a 2′5′ nucleotide or a mirror nucleotide is present in at least one of positions 5, 6, 7, 8, or 9 from the 5′ terminus of the antisense strand.

### Claim at position 9

11-12. (canceled)

### Claim 13 (depends on 10)

The double stranded nucleic acid molecule of claim 10, wherein the antisense strand comprises a 2′-5′ nucleotide in position 5, in position 6, in position 7, in position 8, in position 9, in positions 5-6, in positions 6-7, in positions 7-8, in positions 8-9, in positions 5-7, in positions 6-8, in positions 7-9, in positions 5-8, in positions 6-9, or in positions 5-9.

### Claim 14 (depends on 13)

The double stranded nucleic acid molecule of claim 13, wherein the antisense strand comprises a 2′-5′ nucleotide in position 5, in position 6, in position 7, or in position 8.

### Claim 15 (depends on 10)

The double stranded nucleic acid molecule of claim 10, wherein the antisense strand comprises a mirror nucleotide in position 5, in position 6, in position 7, in position 8, in position 9, in positions 5-6, in positions 6-7, in positions 7-8, in positions 8-9, in positions 5-7, in positions 6-8, in positions 7-9, in positions 5-8, in positions 6-9, or in positions 5-9.

### Claim 16 (depends on 15)

The double stranded nucleic acid molecule of claim 15, wherein the antisense strand comprises a mirror nucleotide in position 5, in position 6, in position 7, or in position 8.

### Claim at position 14

17-20. (canceled)

### Claim 21 (depends on 1)

The double stranded nucleic acid molecule of claim 1, wherein the sense strand comprises at least four consecutive 2′5′ nucleotides at the 3′ terminal or penultimate position.

### Claim at position 16

22-23. (canceled)

### Claim 24 (depends on 21)

The double stranded nucleic acid molecule of claim 21, wherein the sense strand comprises 2′5′ nucleotides in positions 15, 16, 17, and 18, or in positions 16, 17, 18, and 19.

### Claim 25 (depends on 1)

The double stranded nucleic acid molecule of claim 1, further comprising at least one 2′OMe sugar modified ribonucleotide in the antisense strand.

### Claim 26 (depends on 1)

The double stranded nucleic acid molecule of claim 1 further comprising at least one 2′OMe sugar modified ribonucleotide in the sense strand.

### Claim 27 (depends on 25)

The double stranded nucleic acid molecule of claim 25, wherein the 2′OMe sugar modified ribonucleotides are present in positions 2, 4, and 6 from the 5′ terminus of the antisense strand.

### Claim 28 (depends on 1)

The double stranded nucleic acid molecule of claim 1 comprising z″ covalently attached at the 5′ terminus of the sense strand.

### Claim 29 (depends on 28)

The double stranded nucleic acid molecule of claim 28, wherein z″ is an abasic moiety.

### Claim 30 (depends on 1)

The double stranded nucleic acid molecule of claim 1 comprising Z covalently attached to the 3′ terminus of the antisense strand or Z′ covalently attached to the 3′ terminus of the sense strand, or both Z covalently attached to the 3′ terminus of the antisense strand and Z′ covalently attached to the 3′ terminus of the sense strand.

### Claim 31 (depends on 30)

The double stranded nucleic acid molecule of claim 30, wherein Z and Z′ independently comprise one or two non-nucleotide moieties.

### Claim 32 (depends on 31)

The double stranded nucleic acid molecule of claim 31, wherein Z and Z′ independently comprise C3PiC3Pi or C3PiC3OH moieties.

### Claim 33

(canceled)

### Claim 34 (depends on 1)

The double stranded nucleic acid molecule of claim 1, wherein the target RNA comprises human mRNA or viral RNA.

### Claim 35

(canceled)

### Claim 36 (depends on 1)

A composition comprising the double stranded nucleic acid molecule of claim 1 and a pharmaceutically acceptable carrier.

### Claim 37 (depends on 1)

A method for treating a disease or condition in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a double stranded nucleic acid molecule of claim 1.

### Claim 38 (depends on 37)

The method of claim 37, wherein the subject is a human subject.

### Claim 39 (depends on 37)

The method of claim 37, wherein the disease or the condition is selected from the group consisting of hearing loss, acute renal failure (ARF), Delayed Graft Function (DGF) after kidney transplantation, glaucoma, ocular ischemic conditions, including non-arteric ischemic optic neuropathy (NAION), anterior ischemic optic neuropathy, age-related macular degeneration (AMD), Ischemic Optic Neuropathy (ION) and dry eye syndrome, acute respiratory distress syndrome (ARDS), and other acute lung and respiratory injuries, chronic obstructive pulmonary disease (COPD), primary graft failure, ischemia-reperfusion injury, reperfusion injury, reperfusion edema, allograft dysfunction, pulmonary reimplantation response, and/or primary graft dysfunction (PGD) after organ transplantation, organ transplantation including lung, liver, heart, pancreas, and kidney transplantation, nephro- and neurotoxicity, spinal cord injury, brain injury, neurodegenerative disease or condition, pressure sores, oral mucositis, fibrotic disorders, Menieres disease, and cancer.

### Claim at position 33

40-71. (canceled)
